MedPath

Wii Fit and cerebral palsy feasibility study

Not Applicable
Completed
Conditions
Cerebral Palsy
Nervous System Diseases
Registration Number
ISRCTN17624388
Lead Sponsor
Sussex Community NHS Trust
Brief Summary

2019 results in https://pubmed.ncbi.nlm.nih.gov/31131641/ (added 26/08/2020)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
31
Inclusion Criteria

1. Inclusion criteria for questionnaire (phase one of study):
1.1. Parents of children with cerebral palsy of any level (ie GMFCS 1-5)
1.2. Child aged 5 to 16 years old
1.3. Under management of Sussex Community NHS Trust identified from local clinical database

2. Inclusion criteria for randomised, single blind, controlled study (phase two of study):
2.1. Ambulatory Bilateral and Unilateral CP
2.2. GMFCS types I and II e.g. able to walk without a walking aid
2.3. Ability to follow simple task instruction
2.4. All school ages -from 5 up to the age of 16; primary -5 to 11 years and secondary >11 – 16 years, (Upper limit of 16 to avoid timetabling variations at 6th form programmes)
2.5. Under management of Sussex Community NHS Trust, identified from local clinical database

Exclusion Criteria

1. Exclusion criteria for questionnaire (phase one of study):
1.1. Child aged less than 5 or over 16 years old

2. Exclusion criteria for randomised, single blind, controlled study (phase two of study):
2.1. Children who are GMFCS III, IV, V
2.2. Child/Family unable to follow simple task instructions in English
2.3. Over the age of 16, outside of school age
2.4. Child with epilepsy who is photosensitive and has had a seizure within the last year
2.5. On anticonvulsant medication

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> 1. Gross Motor Function Measurement (GMFM)<br> 2. Bruininks-Oseretsky test of motor proficiency (BOT-2)<br> 3. Timed up and go test (TUG)<br> 4. Goal Attainment Scale (GAS)<br> 5. Strengths and Difficulties Questionnaire<br><br> Measurements will be taken at baseline (week 1), midway (week 6), and exit of trial period (week 12). Measurements will be taken by blinded members of the trial team.<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath